Orzax Reports Strong Growth in First Half of 2026: Revenue Reaches TRY 4.5 Billion

Orzax’s revenue rose 36 per cent to TRY 4.53 billion in the first half of 2026. The company aims to accelerate its global growth through production capacity investments, overseas facilities and R&D work.

Orzax, which has operated in the food supplement sector for more than 22 years, has reported its financial results for the first half of 2026 to the Public Disclosure Platform (KAP). Announcing its first financial results since its public offering, the company delivered strong growth in the first half of the year.

Orzax’s revenue in the first half of 2026 rose 36 per cent year on year to TRY 4,525,914,000. The company’s gross profit came in at TRY 2,963,471,000 and EBITDA at TRY 1,368,699,000. The EBITDA margin was recorded at 30 per cent, and the company closed the period with a net profit of TRY 306 million.

A 36 million box increase in production capacity
Orzax is supporting its strong market position in Türkiye with production capacity investments and international growth. With a distribution network reaching some 30,000 pharmacies across Türkiye, the company is continuing to invest in expanding its production capacity in order to meet rising demand.

While making investments to increase production capacity by 36 million boxes, the company aims to raise the share of exports in total revenue to 35 per cent within the next five years.

New investments for global growth
International investment occupies an important place in Orzax’s growth strategy. In July 2026 the company laid the foundations of its EUR 35 million factory in Kazakhstan, its largest overseas investment to date. EUR 25 million of the investment is being financed by the European Bank for Reconstruction and Development (EBRD).

The company has also strengthened its structure in the Indian market. The establishment of a subsidiary named ORZAX LIFE SCIENCES PRIVATE LIMITED in the Indian state of Delhi has been completed, marking an important step towards operating directly in the country. Orzax has also completed the establishment of a subsidiary in Uzbekistan.

Growth expectations in the global dietary supplements market also support the company’s internationalisation strategy. According to Grand View Research data, the global dietary supplements market, which reached USD 209.5 billion in 2025, is expected to grow at a compound annual rate of 9.5 per cent over the 2026–2033 period.

R&D work for a domestic probiotic raw material
Alongside its production and overseas investments, Orzax also positions R&D and innovation as one of its new growth areas.

The company aims to produce domestic probiotic raw materials and finished products from bacteria isolated in Türkiye. The aim of this work is both to reduce dependence on imports and to take a share of the global probiotics market, which is worth more than USD 70 billion.

Yunus Emre Alimoğlu: “We are moving decisively towards our global growth targets”
Orzax CEO Yunus Emre Alimoğlu said the company’s financial performance in the first half of 2026 was an indication of its sustainable growth strategy.

Alimoğlu said: “The TRY 306 million net profit we achieved in the first half of 2026 and the 52 per cent increase in net profit compared with the same period last year were an indication of our sustainable growth strategy and our strong operational structure. By increasing our revenue by 36 per cent and our operating profit by 24 per cent year on year, we continued to move forward with strong and determined steps in our core business lines.”

Turning to Orzax’s medium and long-term growth targets, Alimoğlu said: “In line with our sustainable growth strategy, we are moving forward with confidence towards our target of 25 per cent compound annual growth over the 2023–2027 period and of tripling our sales to reach TRY 22 billion in turnover by 2029.”

Alimoğlu continued:

“While strengthening our presence in strategic markets such as the United States, the United Kingdom, Germany, Poland and Kazakhstan, we are also bringing new growth engines into play through the importance we attach to R&D and innovation. By producing domestic probiotic raw materials and finished products from bacteria isolated in Türkiye, we aim both to reduce import dependence and to take a share of the huge global market worth more than USD 70 billion. With the support of our investors and stakeholders, we will continue with determination to create value both at home and on the global stage.”